Long-term efficacy and safety of infliximab in the treatment of behçet's disease

Ocular Immunology and Inflammation

Volumn 20, Issue 3, 2012, Pages 198-202

  Capella, María José ^a   Foster, C Stephen ^b,c  

^a INSTITUT UNIVERSITARI BARRAQUER   (Spain)

^b MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^c Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

Beh et's disease; Biologics; Corticosteroid sparing; Infliximab; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GOLIMUMAB; INFLIXIMAB; INTERFERON; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TOCILIZUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHCET DISEASE; CLINICAL ARTICLE; DEMYELINATING NEUROPATHY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; LEG EDEMA; LEUKOPENIA; MALE; NAUSEA; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; REMISSION; RETROSPECTIVE STUDY; SERUM SICKNESS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISUAL ACUITY; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84860523780     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.670360     Document Type: Article

References (28)

1. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
2. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297-350. (Pubitemid 40828225)
3. Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986;70:589-92. (Pubitemid 16038279)
4. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's dis-ease-an update. Semin Arthritis Rheum 2001;30:299-312.
5. Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behçet's disease. J Rheumatol 1990;17:1428-9. (Pubitemid 20382885)
6. Gül A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19:S6-12.
7. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251-5. (Pubitemid 34701624)
8. Turan B, Gallati H, Erdi H et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32. (Pubitemid 27059870)
9. Arayssi T, Hamdan A. New insights into the pathogen-esis and therapy of Behçet's disease. Curr Opin Pharmacol 2004;4:183-8. (Pubitemid 38444055)
10. Maini SR. Infiximab treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:329-47.
11. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in infammatory bowel disease. Gastroenterology 2004;126:1593-610. (Pubitemid 38649876)
12. Braun J, Sieper J. Biological therapies in the spondyloar-thritides-the current state. Rheumatology (Oxford) 2004;43: 1072-84. (Pubitemid 39232810)
13. Sfkakis P P, Theodossiadis PG, Katsiari CG et al. Effect of inf-liximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6. (Pubitemid 32738970)
14. Ohno S, Nakamura S, Hori S et al. Effcacy, safety, and phar-macokinetics of multiple administration of infiximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8. (Pubitemid 38879203)
15. Triolo G, Vadalà M, Accardo-Palumbo A et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-1. (Pubitemid 34539106)
16. Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Effcacy of infiximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-84. (Pubitemid 41117435)
17. Yamada Y, Sugita S, Tanaka H et al. Comparison of infix-imab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 2010;94:284-8.
18. Tabbara KF, Al-Hemidan AI. Infiximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008;146:845-50.
19. Al-Rayes H, Al-Swailem R, Al-Balawi M et al. Safety and effcacy of infiximab therapy in active behcet's uveitis: an open-label trial. Rheumatol Int 2008;29:53-7.
20. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007;1110:474-84. (Pubitemid 350043037)
21. Accorinti M, Pirraglia MP, Paroli MP et al. Infiximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007;51:191-6. (Pubitemid 46889493)
22. Niccoli L, Nannini C, Benucci M at al. Long-term effcacy of infiximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007;46:1161-4. (Pubitemid 47050622)
23. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and effcacy of infiximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005;26:83-92. (Pubitemid 44781873)
24. Lanthier N, Parc C, Scavennec R et al. Infiximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005;34:916-8.
25. Wechsler B, Sablé-Fourtassou R, Bodaghi B et al. Infiximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004;22:S14-6.
26. Sfkakis PP, Kaklamanis PH, Elezoglou A et al. Infiximab for recurrent, sight-threatening ocular infamma-tion in Adamantiades-Behçet disease. Ann Intern Med 2004;140:404-6. (Pubitemid 38268925)
27. Yazici H, Pazarli H, Barnes CG, Tüzün Y et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5. (Pubitemid 20046329)
28. Masuda K, Nakajima A, Urayama A et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6. (Pubitemid 19128039)